Wang Anbang, Qu Le, Wang Linhui
Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Department of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China.
Cancer Lett. 2017 Jan 28;385:87-96. doi: 10.1016/j.canlet.2016.10.039. Epub 2016 Nov 2.
Small-molecule targeted therapy (TT) has brought great hopes to patients with advanced malignancies. However, most patients suffer from tumor progression and relapse due to drug resistance. Recently, considerable efforts trying to elucidate the underlying mechanisms have focused on the contribution of cancer stem cells (CSCs) to the targeted therapy resistance (TTR). In this article, we provide an overview of the currently available literature on the rising roles of CSCs in TTR, as well as therapeutic opportunities of combining TT and anti-CSC therapy in the treatment of advanced malignancies.
小分子靶向治疗（TT）给晚期恶性肿瘤患者带来了巨大希望。然而，大多数患者因耐药性而出现肿瘤进展和复发。最近，为阐明潜在机制所做的大量努力聚焦于癌症干细胞（CSC）对靶向治疗耐药性（TTR）的作用。在本文中，我们概述了目前关于CSC在TTR中日益重要作用的现有文献，以及在晚期恶性肿瘤治疗中联合TT和抗CSC治疗的治疗机会。
